Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Announces Two Key Leadership Team Appointments
- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration
Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials
View HTML
Toggle Summary AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced industry veterans to board and management team-
View HTML
Toggle Summary AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases
View HTML
Toggle Summary AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study
AGTC patient advocacy executive director and director of patient enrollment to speak at Clinical Trials in Rare Diseases Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation  (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Visionary science for life changing cures.